Mark Walker

Professor Mark Walker is a Professorial Research Fellow & Group Leader at the Institute for Molecular Bioscience, The University of Queensland. He holds an affiliation with the Centre for Superbug Solutions. His research focuses on medical microbiology, specifically the pathogenesis, evolution, and control of Group A Streptococcus (GAS) infections. Key areas include vaccine development, antibiotic resistance mechanisms, and molecular diagnostics.

Walker earned his Doctor of Philosophy from The University of Queensland. His work spans clinical, genomic, and immunological studies, addressing global health challenges such as scarlet fever epidemics and multidrug-resistant pathogens.

His research interests include GAS pathogenesis, vaccine candidate evaluation, and the molecular basis of bacterial virulence. Recent studies emphasize the role of M proteins, superantigens, and host-pathogen interactions in disease progression. He has contributed to breakthroughs in repurposing drugs like PBT2 to combat antibiotic resistance.

Over 247 publications reflect his interdisciplinary approach, combining omics, clinical trials, and translational research. He leads major grants from NHMRC, CARB-X, and industry partners, totaling millions in funding. His supervision spans 10+ PhD students investigating vaccine efficacy, antibiotic modulators, and bacterial evolution.

Walker collaborates globally, with projects in Australia, the U.S., and China. His lab’s innovations include mRNA vaccine development and novel antimicrobial strategies, aiming to reduce global infectious disease burden.